Jonathan Thompson, MD, MS

Assistant Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine
MS -Master of Science

Biography

Dr. Thompson is an Assistant Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology who joined the faculty in July 2017. He received his medical degree from the Medical College of Wisconsin in 2010 and completed internal medicine residency and hematology/oncology fellowship training at the Medical College of Wisconsin Affiliated Hospitals. He is board certified in internal medicine, hematology, and medical oncology. Dr. Thompson’s area of clinical interest is thoracic oncology, including lung cancers, mesothelioma and thymic malignancies. He is interested in clinical and translational research, particularly pertaining to immunotherapy and the treatment of lung cancer.

Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy.

(Simone CB 2nd, Serebrenik AA, Gore EM, Mohindra P, Brown SL, Wang D, Chetty IJ, Vujaskovic Z, Menon S, Thompson J, Fine G, Kaytor MD, Movsas B.) Int J Radiat Oncol Biol Phys. 2024 Feb 01;118(2):404-414 PMID: 37652301 SCOPUS ID: 2-s2.0-85172016695 09/01/2023
Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRASG12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report

(Stratton N, Thompson J.) JTO Clinical and Research Reports. April 2024;5(4) SCOPUS ID: 2-s2.0-85188614847 04/01/2024
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.

(Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S, SAPPHIRE Investigators.) Ann Oncol. 2024 Jan;35(1):66-76 PMID: 37866811 SCOPUS ID: 2-s2.0-85178324517 10/23/2023
Resected cytokeratin-negative small cell lung carcinoma.

(Jain PV, Thompson J, Sheinin Y.) BMJ Case Rep. 2023 Apr 03;16(4) PMID: 37011997 PMCID: PMC10083812 SCOPUS ID: 2-s2.0-85151707665 04/04/2023
Comprehensive genomic profiling: Does timing matter?

(Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B.) Front Oncol. 2023;13:1025367 PMID: 36865796 PMCID: PMC9971445 03/04/2023
The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models

(Joe R, Matsumura Y, Siddiqui A, Foulks J, Beg M, Thompson J, Yamamoto N, Spira A, Sarantopoulos J, Melear J, Lou Y, Lebedinsky C, Li J, Watanabe A, Warner S.) European Journal of Cancer. October 2022;174:S57-S58 SCOPUS ID: 2-s2.0-85140454116 10/01/2022
Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology

(Sherry-Ann Brown, Svetlana Zaharova, Peter Mason, Jonathan Thompson, Bicky Thapa, David Ishizawar, Erin Wilkes, Gulrayz Ahmed, Jason Rubenstein, Joyce Sanchez, David Joyce, Balaraman Kalyanaraman, Michael Widlansky.) Frontiers in Cardiovascular Medicine. Front. Cardiovasc. Med., 04 December 2020 12/04/2020
Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.

(Brown SA, Zaharova S, Mason P, Thompson J, Thapa B, Ishizawar D, Wilkes E, Ahmed G, Rubenstein J, Sanchez J, Joyce D, Kalyanaraman B, Widlansky M.) Front Cardiovasc Med. 2020;7:568720 PMID: 33344513 PMCID: PMC7746643 SCOPUS ID: 2-s2.0-85115906217 12/22/2020
QOLP-01. OUTCOME ASSESSMENT OF MULTIDISCIPLINARY BRAIN TUMOR BOARD MEETING RECOMMENDATIONS FOR BRAIN METASTASIS: IS THERE A GAP?

(Fernando Santos-Pinheiro, Joseph Bovi, Wendy Peltier, Jennifer Connelly, Wade Mueller, Michael Straza, Lindsay Puckett, Marianne Crabb, Julianne Leuck, Nathan Zwagerman, Jonathan Thompson, Christopher Schultz, Jennifer Lindstedt, Kimberly Roller-Voigt, Ariel Nelson, Sarah Bichler, Alexandra Leutenegger, Tracy Erlitz, Carolyn Brausch, Hina Saeed, Dustin Hahn, Fernando Santos-Pinheiro.) Neuro-Oncology. Volume 22, Issue Supplement_2, November 2020, Page ii174 11/09/2020
INNOVATIVE USE OF A CUSTOM MOBILE APPLICATION (APP) BY A BRAIN METASTASES PROGRAM FACILITATES MULTIDISCIPLINARY MANAGEMENT OF PATIENTS AND DECREASED LENGTH OF HOSPITAL STAY (LOS)

(Joseph Bovi, Jennifer Lindstedt, Fernando Santos-Pinheiro, Wade Mueller, Straza Michael, Lindsay Puckett, Jonathan Thompson, Ariel Nelson, Wendy Peltier, Carolyn Brausch, Tracy Erlitz, Heather Meerstein, David Atkinson, Marianne Crabb, Julianne Leuck, Kimberly Roller-Voigt, Christopher Schultz.) Neuro-Oncology Advances. Volume 2, Issue Supplement_2, August 2020, Page ii7 08/04/2020
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

(Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C.) J Immunother Cancer. 2019 Feb 01;7(1):27 PMID: 30709424 PMCID: PMC6359802 SCOPUS ID: 2-s2.0-85060929943 02/03/2019
A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy

(Enriqueta Felip, Paal Brunsvig, Nuria Vinolas, Santiago Ponce Aix, Enric Carcereny Costa, Manuel Dómine Gomez, Jose Manuel Trigo Perez, Edurne Arriola, Rosario Garcia Campelo, James F. Spicer, Jonathan Robert Thompson, Ana Laura Ortega Granados, Robert J Holt, Katherine Lorens, James B. Lorens, Muhammad Shoaib, Abdul Siddiqui, Emmett V. Schmidt, Michael Jon Chisamore, Matthew Krebs.) J Clin Oncol. J Clin Oncol 37, 2019 (suppl:abstr 9098) 06/02/2019